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Rates of acquisition and clearance of cervical human
papillomavirus (HPV) during a 3-year period in women 51
years of age were compared with rates in younger women
to provide data on cervical screening for women >50 years
of age. Paired, cytologically negative, archived cervical
smears taken 3 years apart from 710 women in
Nottingham, United Kingdom, were retrieved and tested for
HPV infection with polymerase chain reaction (PCR) with
GP5+/6+ primers. Seventy-one (21.3%) of 333 women 51
years of age who were HPV negative at baseline were pos-
itive 3 years later. This percentage was higher than the cor-
responding acquisition rates among women 21 (15.2%), 31
(14.1%), and 41 (13.3%) years of age, although these dif-
ferences were not significant. This retrospective study
shows that HPV-negative women >50 years of age can
acquire HPV and, therefore, require cervical screening.
P
rospective studies of young women (<25 years of age)
have reported high rates of cervical human papillo-
mavirus (HPV) acquisition; the average duration of these
infections is <1 year (1–4). Little evidence shows that the
converse is true among older women, considering the
decline in HPV prevalence that has been found with age
(5,6). In studies from Brazil and Colombia, an incidence of
high-risk (carcinogenic) HPV of ≈5% per year was
observed among women >35 years of age (7,8); recent data
from Costa Rica showed that the rate of high-risk HPV
acquisition during a 5-year interval decreased slightly with
increasing age (9). All these studies were conducted in
areas where the risk of cervical cancer is considered to be
high. In a small study from Canada, 7.7% of women 45–49
years of age who were negative for high-risk HPV at base-
line tested positive 1 year later, similar to the rate in
women 20–25 years of age (10). From studies of women in
adulthood, estimates of the percentage of HPV infections
(high and low risk) that persist >12 months range from
25% to 50% (10–13); HPV persistence after 5 years
increased with age in the study from Costa Rica (9).
Data on acquisition and clearance of HPV in women
50–64 years of age in the United Kingdom and other
Western nations are needed. The presence of HPV is a req-
uisite to develop invasive cancer of the cervix (14).
Therefore, women within this age range with cytological-
ly negative specimens, tested with a sensitive testing
method such as the polymerase chain reaction (PCR),
should have a virtually zero lifetime risk of developing
cervical cancer, unless they acquire a new HPV infection.
A mathematic modeling study based on the UK screening
population estimated that not providing screening for
HPV-negative women at age 50 would save as much as
25% of resources for smear tests and 18% for colpo-
scopies; however, the savings would be accompanied by
an increase in the incidence of invasive cancers of
≈2/100,000 women annually (15). These estimates would
be more accurate if the risk of acquiring high-risk HPV
infection at these ages was known.
In this study, archived cervical smears were used to
compare rates of HPV acquisition during a 3-year period
(1 screening interval in the United Kingdom) between
women of different ages. This approach also allowed us to
estimate rates of HPV persistence and clearance during the
same 3-year interval for women whose baseline smears
were HPV positive.
Methods
Anonymous data were provided by the Nottingham
Cervical Screening Laboratory, which holds computerized
details of all cytology smears of women who have lived in
Nottingham since 1987. This laboratory also stores all
specimens from women for whom routine cervical screen-
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Kingdomings were conducted by general practitioners in this area.
All specimens used for this study were cytologically nor-
mal and had been stored for >10 years (in accordance with
UK legal requirements) but were scheduled for routine
destruction.
Women eligible for this study were 21, 31, 41, or 51
years of age when a normal baseline smear was taken in
1988. We intended to select a sample of 400 women 51
years of age and 100 women from each of the other age
groups to participate in the study. The main entry criterion
was a normal cervical smear taken in 1988, followed by a
technically adequate subsequent smear (of any cytologic
grade) taken from October 1990 to December 1991. The
sample for women 51 years of age was supplemented by
including women whose baseline smear was obtained in
1989 and who had a subsequent smear taken before July
1992; all eligible women of this age were selected. Women
21, 31, or 41 years of age were selected randomly from the
list of participants who met the main entry criteria. For all
participants, results from subsequent cytology examina-
tions conducted through December 2002 were provided by
the Nottingham Cervical Screening Laboratory, including
any cervical biopsy results from which histologic confir-
mation of cervical intraepithelial neoplasia (CIN, grades
1–3) or cervical cancer was obtained.
When cytology slides were retrieved for HPV testing,
all identifiers (name, date of birth, and cytology number)
were replaced with a unique study number. Only investiga-
tors based at the cytology laboratory (P.V., J.J.) had access
to clinical data. These investigators did not have access to
HPV testing results for specific patients. Another investi-
gator (M.G.) was responsible for linking HPV test results
from the same patient with subsequent cytology results and
had access to data on screening histories but not informa-
tion through which patients could be identified. The study
was approved by the Nottingham City Hospital ethics
committee.
Cytology slides were immersed in xylene (40 mL) for
2–3 days to remove coverslips. Cells were then scraped
with a sterile scalpel blade into an Eppendorf tube contain-
ing ethanol (1 mL) and centrifuged to remove any trace of
xylene. DNA was extracted by using Qiagen (Crawley,
West Sussex, United Kingdom) DNA extraction kits (16).
HPV DNA was amplified by using real time PCR with
Mx4000 (Stratagene, La Jolla, CA, USA) (17). The GP5+
and GP6+ consensus primer pairs in the L1 region of the
HPV genome identified infection with any genital HPV
type (18). The PCR master mix Quantitect (Qiagen) (19)
contained optimized amounts of SYBR green dye
(Molecular Probes, Inc., Eugene, OR, USA) to which
primers (5 pmoL/tube) and DNA template (5 µL) were
added. Positive controls containing tubes of HPV 16 DNA
diluted at various strengths (0.01–10 pg/tube) and negative
controls containing the PCR master mix but no DNA tem-
plate were included in all assays. Forty amplification
cycles were performed. Samples that were HPV positive
with the GP5+/6+ primer sequence were tested with type-
specific HPV16 and HPV18 primers located in the E7
667–686 and 753–774 regions of the genome, respectively
(Sequences: HPV16 forward primer, 5′-GAT GAA ATA
GAT GGT CCAGC-3′; HPV 16 reverse primer, 5′-GCT
TTG TAC GCA CAA CCG AAG C-3′; HPV18 forward
primer, 5′-TGA AAT TCC GGT TGA ACC TTC-3′; and
HPV 18 reverse primer, 5′GGT CGT CTG CTG AGC TTT
CT-3′). A total of 471 cervical DNA samples collected for
related studies (although not from women in this study)
were tested for the β-globin gene to assess the integrity of
the DNA extraction process; 456 (96.8%) tested β-globin
positive.
HPV acquisition was calculated as the percentage of
women who were HPV negative at baseline but HPV pos-
itive on follow-up (and the converse applied for HPV
clearance). Clearance of baseline infections was assumed
if the equivalent test at follow-up was negative.
Nonsymmetric confidence intervals were calculated to
measure acquisition and clearance, as these are more
appropriate when observed percentages are low (20). Rates
of HPV acquisition in women of different ages were com-
pared with the χ2 test; Fisher exact test was used as a con-
sequence of small numbers for HPV clearance. Rates of
HPV prevalence (at baseline and follow-up), acquisition,
and clearance across the 4 ages were compared by using
the χ2 test for trend.
Results
Cervical smears were retrieved for HPV testing for 710
women (104 were 21 years of age, 105 were 31 years of
age, 105 were 41 years of age, and 396 were 51 years of
age). Of the study sample (N = 710), 11 were subsequent-
ly excluded because of a cervical abnormality before their
baseline smear. Follow-up smears could not be retrieved
for 27 women; the smear was cytologically abnormal in 20
cases, and the follow-up smear could not be retrieved in
the 7 remaining cases. Sixteen women were excluded
because an HPV result could not be ascertained at either
time because of insufficient DNA. The final sample was
656 women. The mean length of time between the baseline
and follow-up smear was 3.08 years (range 1.98–3.84
years). For 76% of the sample (n = 499), the time gap was
2.75–3.25 years. The average time gap between the smears
did not vary substantially between age groups. 
Rates of HPV infection in this sample are shown in
Table 1. In 1988, rates of HPV infection declined with age;
the lowest rate was seen in women 51 years of age
(10.5%). Three years later, the trend was reversed with the
highest rate of HPV in women who were 51 years of age
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age was significant at baseline and borderline significant at
follow-up (Table 1).
Age-specific rates of HPV acquisition and clearance
(any genital type amplified by the GP5+/6+ primer pair)
are shown in Table 2. The HPV acquisition rate was high-
est for women who were 51 years of age at baseline,
although this rate was not significantly higher than the cor-
responding rate for any of the other ages. A test for trend
in the acquisition rates across the 4 ages reached borderline
significance (χ2 trend = 3.18, p = 0.07). Clearance of HPV
infection was lowest for women 51 years of age, although
again, no substantial differences were observed between
this rate and those for the other 3 ages, and the trend in
clearance rates across the 4 ages was not significant (χ2
trend = 0.72, p = 0.40). When analyses for overall HPV
acquisition and clearance were conducted again and
included the 20 women with abnormal cytology at follow-
up, assuming that these were HPV positive, the results for
both HPV acquisition and clearance remained similar.
Type-specific HPV acquisition and clearance rates are
shown in Table 3. Twenty (11 in women 51 years of age)
new HPV16 infections were found in this sample; 24 (14
in women 51 years of age) new HPV18 infections were
found. The low number of new HPV16 and HPV18 infec-
tions meant that the confidence intervals for the estimated
rates of acquisition of these types were wide. Linear trends
to assess rates of acquisition across age were not signifi-
cant for either HPV16 (χ2 trend 0.08, p = 0.77) or HPV18
(χ2 trend 0.02, p = 0.89). Three women (21, 31, and 51
years of age, respectively) acquired both HPV16 and
HPV18 infections at follow-up, after testing negative for
both at baseline. Of the 27 HPV16 or HPV18 infections
that were found at baseline over all 4 ages, only 3 were still
present at the time of follow-up. This finding indicated
overall clearance rates were close to 90% for both HPV16
and HPV18 (Table 3). 
Abnormal findings, including symptoms of mild sever-
ity in 10 women and moderate severity in 6 women, devel-
oped in 38 women in this study during a follow-up period
of 11 years; severe dyskaryosis developed in 5 women.
CIN or cancer was histologically confirmed in 8 women;
CIN grade 1 was diagnosed in 4 women, CIN 3 was diag-
nosed in 3, and invasive squamous carcinoma was diag-
nosed in 1. Cytologic and histologic results stratified by
HPV status in 1988 and 1991 are summarized in Table 4.
Rates of cervical abnormality during follow-up were
slightly higher for women who were HPV positive at base-
line, although HPV status at either time was not signifi-
cantly associated with subsequent abnormal cytologic
results (Table 5). Two of the 5 women with severe
dyskaryosis, however, had acquired HPV at the time of the
second smear (Table 4). Both of these women were 51
years of age at baseline. Squamous carcinoma was diag-
nosed in 1 of these women in 1998 (7 years after HPV was
detected). This woman was negative for HPV types 16 and
18. The other woman also had the cytologic diagnosis in
1998; however, no biopsy result was recorded on this occa-
sion. This woman was positive for both HPV16 and
HPV18 at baseline.
Discussion 
Our study found a high 3-year rate of HPV acquisition
rate in women 51 years of age at baseline. Although differ-
ences in HPV acquisition with age were not statistically
significant, this rate was at least as high as that observed
among younger women. This rate is equivalent to the 1-
year acquisition rate for high-risk HPV in a Canadian
study of a sample of 39 women 45–49 years of age (10).
Our estimated incidence among 51-year-old women was
slightly higher than the rate of high-risk HPV (6.1/100)
found in 50- to 54-year-old women in a study from
Colombia (8), a country with a high rate of cervical cancer.
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this study was ≈7%. Only type-specific PCR was conduct-
ed for these types, a limitation of this study. Further
research is, therefore, required to estimate the combined
acquisition rate for all high-risk HPV among older women
(and, conversely, to determine whether a substantial pro-
portion of incident infections are with low-risk HPV). 
A selection criterion for this study was a cytologically
normal cervical smear taken during 1988. In the United
Kingdom, changes to the cervical screening program had
just been implemented at that time, and coverage rates of
the UK screening population were ≈50% (21). Whether
this change could have caused selection bias remains spec-
ulative; women who received cervical screening may have
been at higher risk than all eligible women. Another crite-
rion was that all women in the study have cytologically
normal results at both phases of the study. As stated earli-
er, only a small number of women (n = 20) had abnormal
cytologic findings at follow-up, and when analyses that
indicated these women were HPV positive were conduct-
ed again, no noticeable impact was seen on results.
The high rate of HPV acquisition in 51-year-old women
may be due to either a higher-than-anticipated rate of new
partners among older women or partner infidelity.
However, the former supposition is not supported by data
from 2 large-scale national surveys of sexual behavior
among women in the United Kingdom conducted in 1990
and 2000 (22,23). The second of these surveys found that
only 10.9% of women 35–44 years of age reported a new
sex partner in the year preceding the survey, compared
with 39.2% of women 16–24 years of age (23). Therefore,
a 3-year HPV acquisition rate of 21% for women 51 years
of age would be higher than expected, based solely on the
rate of new partner acquisition among a group of women
35–44 years of age. The 1990 version of this survey, how-
ever, reported that 5.4% of men in the 45- to 59-year age
group reported >2 sex partners during the previous year
(22). While these may not have all been new sex partners,
and the rate just among married (or cohabiting) men may
be lower (separate data not available), this finding indi-
cates that a small part of the total HPV acquisition rate
could be a consequence of partner infidelity. 
Also, the high rate of HPV acquisition in 51-year-old
women may be due to the reemergence of latent HPV
infections caused by hormonal changes resulting from
menopause or alterations to the cervix caused by hormone
replacement therapy. A latent infection can be defined as
one where HPV genomes are established in the basal cells
but differentiation of the host cells does not take place
(24). If such infections were below detection with increas-
ingly sensitive PCR technology until the point of reactiva-
tion, then women could possibly become HPV positive in
the absence of sexual activity. This possibility could also
explain the finding of a second age-related peak in HPV
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prevalence in some South American populations after 55
years of age (6,25,26). However, less evidence for this sec-
ond peak in HPV prevalence is seen in the United
Kingdom and other countries where the risk of cervical
cancer is lower.
Additionally, false-negative results occurring during
the first phase of testing would cause HPV infections pres-
ent at baseline and follow-up (i.e., persistent infections) to
be misclassified as incident infections, therefore overesti-
mating rates of HPV acquisition. This study relied on
archived cervical smears taken a decade earlier to detect
HPV infection. While studies have validated the use of this
type of specimen by showing agreement between results
from archived and fresh specimens from the same women
(27), concerns exist that the quality of extracted DNAmay
be poorer for older specimens because of changes in the
methods of sampling and fixation (28).
A less understood but still plausible reason for these
results also relates to the use of archived cervical smears;
the possibility of cross-contamination of samples at the
time of collection could have accounted for false-positive
results at the second phase of testing. This contamination
could have occurred either where cervical smears were
taken or at the screening laboratory during fixation and
staining. In a study from Sweden, this risk of cross-con-
tamination was largely excluded when smears with regis-
tration numbers adjacent to the HPV-positive study smears
were also tested for HPV (29). Results from this study are
difficult to generalize to the present setting, where the risk
of such cross-contamination could only be assessed if the
quality of procedures conducted in doctors’ offices and
screening laboratories between 1988 and 1991 could be
examined. 
This report also contains details of HPVinfection 3-year
clearance rates for women who tested positive in the first
phase of the study. As baseline rates of HPV infection in
this sample were 10%–25%, depending on age (Table 1),
few smears were included for comparison in the analysis
of HPV clearance, which resulted in insufficient statistical
power for clearance rates between women of different ages
to be compared. Among women 51 years of age, a 74%
HPV 3-year clearance rate was observed. The potential for
false-negative results at the second phase of testing means
that these HPV clearance rates are likely overestimated.
In the United Kingdom, screening intervals were
recently lengthened to 5 years for women 50–64 years of
age, after an analysis of UK screening data showed that the
protective effect after a negative cervical smear persisted
longer for older women (30). Whether cervical screening
could be discontinued after 50 years of age for low-risk
women has also been debated (31–33). Whether HPV test-
ing could identify low-risk women would depend on the
natural history of the virus in older women and the person-
al and social implications of introducing a test for a sexu-
ally transmitted disease into a national screening program
(34). Our findings do not support discontinuing cervical
screening for HPV-negative women at age 50 because of
the high risk of HPV acquisition observed in women 51
years of age during a 3-year interval. By conducting a
prospective study in which follow-up is ensured over a
period of time at 4- to 6-month intervals, many of the lim-
itations of this study could be circumvented. The probabil-
ity of viral persistence and progression of incident HPV
infections among older women in the United Kingdom and
other western countries also should be recognized, as only
persistent HPV infections lead to cervical cancer (35).
Outcome data from this study are limited; further data are
required from larger prospective studies to determine more
precisely the positive and negative predictive values (for
high-grade CIN and cancer) of incident HPV infections
that develop in middle age. These issues require consider-
ation before the true impact of discontinuing cervical
screening programs worldwide for HPV-negative women
>50 years of age can be accurately ascertained. 
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